m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05077
 [1], [2]
Non-coding RNA CircBACH2 miR-944  lncRNA       miRNA   circRNA Indirect Enhancement m6A modification WDR77 WDR77 HNRNPC : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) READER
 Regulator Info 
m6A Target Methylosome protein WDR77 (WDR77)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_BACH2 circRNA View Details
Regulated Target hsa-miR-944 View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary Analysis and validation of m6A regulatory network: a novel Circ_BACH2/hsa-miR-944/HNRNPC axis in breast cancer progression.HNRNPC was highly expressed in breast cancer, and played a crucial role in cell growth, especially in the luminal subtype. HNRNPC could combine and stabilize Methylosome protein WDR77 (WDR77) mRNA. WDR77 successively drove the G1/S phase transition in the cell cycle and promoted cell proliferation. Notably, this regulation axis was closely tied to the m6A modification status of WDR77 mRNA. Overall, a critical regulatory mechanism was identified, as well as promising targets for potential treatment strategies for luminal breast cancer.
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
In-vitro Model
 MCF-10A Normal Homo sapiens CVCL_0598
MCF-7 Invasive breast carcinoma Homo sapiens CVCL_0031
T-47D Invasive breast carcinoma Homo sapiens CVCL_0553
SK-BR-3 Breast adenocarcinoma Homo sapiens CVCL_0033
HCC1937 Breast ductal carcinoma Homo sapiens CVCL_0290
BT-549 Invasive breast carcinoma Homo sapiens CVCL_1092
MDA-MB-231 Breast adenocarcinoma Homo sapiens CVCL_0062
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2C60: Breast cancer 2 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Entrectinib Approved [3]
Synonyms
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
    Click to Show/Hide
External Link
CID: 25141092
TTD: D0O0LS
DrugBank: DB11986
 Compound Name Everolimus Approved [4]
External Link
CID: 6442177
TTD: D09ZSC
DrugBank: DB01590
References
Ref 1 Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression. J Transl Med. 2021 Dec 24;19(1):527. doi: 10.1186/s12967-021-03196-4.
Ref 2 HNRNPC promotes estrogen receptor-positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A-dependent manner. Mol Carcinog. 2024 May;63(5):859-873. doi: 10.1002/mc.23693. Epub 2024 Feb 14.
Ref 3 Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.
Ref 4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015